Biotinylated Human IGF-I Protein, His,Avitag™ (SPR verified)
分子别名(Synonym)
IGF-I,IGF1A,somatomedin C,MGF
表达区间及表达系统(Source)
Biotinylated Human IGF-I, His,Avitag (IG1-H82Q6) is expressed from human 293 cells (HEK293). It contains AA Gly 49 - Ala 118 (Accession # P05019-1).
Predicted N-terminus: His
蛋白结构(Molecular Characterization)
This protein carries a polyhistidine tag at the N-terminus, followed by an Avi tag (Avitag™).
The protein has a calculated MW of 11.2 kDa. The protein migrates as 14 kDa under reducing (R) condition (SDS-PAGE) due to glycosylation.
标记(Labeling)
Biotinylation of this product is performed using Avitag™ technology. Briefly, the single lysine residue in the Avitag is enzymatically labeled with biotin.
蛋白标记度(Protein Ratio)
Passed as determined by the HABA assay / binding ELISA.
内毒素(Endotoxin)
Less than 1.0 EU per μg by the LAL method.
纯度(Purity)
>90% as determined by SDS-PAGE.
制剂(Formulation)
Lyophilized from 0.22 μm filtered solution in PBS, pH7.4 with trehalose as protectant.
Contact us for customized product form or formulation.
重构方法(Reconstitution)
Please see Certificate of Analysis for specific instructions.
For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.
存储(Storage)
For long term storage, the product should be stored at lyophilized state at -20°C or lower.
Please avoid repeated freeze-thaw cycles.
This product is stable after storage at:
-20°C to -70°C for 12 months in lyophilized state;
-70°C for 3 months under sterile conditions after reconstitution.
背景(Background)
胰岛素样生长因子1(IGF-1)也称为生长因子C、IGF1A、IGFI、硫酸化因子,是一种分子结构与胰岛素相似的激素。它在儿童成长中起着重要作用,并在成人中继续具有合成代谢作用。mecasermin是IGF-1的合成类似物,用于治疗生长衰竭。IGF-1由单链中的70个氨基酸组成,具有三个分子内二硫键。IGF-1的分子量为7649道尔顿。IGF-1主要由肝脏作为内分泌激素产生,也以旁分泌/自分泌的方式在靶组织中产生。IGF-1与至少两种细胞表面受体结合:胰岛素样生长因子1受体(缩写为“IGF1R”)和胰岛素受体。IGF-1受体似乎是“生理”受体——它与IGF-1的亲和力明显高于与胰岛素受体结合的IGF-1。与胰岛素受体一样,IGF-1受体是一种受体酪氨酸激酶,这意味着它通过在特定的酪氨酸上添加磷酸分子来发出信号。其主要作用是通过与其特异性受体IGF1R结合来介导的,IGF1R存在于许多组织中的许多细胞类型上。与受体酪氨酸激酶IGF1R结合,启动细胞内信号传导;IGF-1是AKT信号通路最有效的天然激活剂之一,是细胞生长和增殖的刺激剂,也是程序性细胞死亡的强效抑制剂。胰岛素样生长因子1已被证明与所有IGF-1结合蛋白(IGFBPs)结合并相互作用,其中有六种(IGFBP1-6)。提供了与IGFBP3、IGFBP4和IGFBP7相互作用的具体参考文献。
关键字: IGF-I;IGF-I蛋白;IGF-I重组蛋白;ACRO;百普赛斯;
百普赛斯集团ACROBiosystems Group(股票代码:301080)是成立于2010年的跨国生物科技公司,是为全球生物医药、健康产业领域提供关键生物试剂产品及解决方案的行业平台型基石企业。2021年在创业板上市。百普赛斯集团业务遍布全球,横跨亚洲、北美洲、欧洲,在中国、美国、瑞士等12个城市设有办公室、研发中心及生产基地。目前累计服务客户超6000家,与全球Top 20医药企业均建立了长期、稳定的合作伙伴关系。集团旗下拥有品牌ACROBiosystems百普赛斯、bioSeedin柏思荟、Condense Capital垦拓资本和ACRODiagnostics百斯医学等。